Medivation (MDVN) – Company Press Releases
-
New Data Presented at ESMO 2016 Further Demonstrates XTANDITM▼ (enzalutamide) Significantly Improves Time to PSA Progression in Advanced Prostate Cancer, Compared with Placebo
-
Pfizer Completes Acquisition of Medivation
-
Medivation Highlights New Data From Differentiated Oncology Portfolio at ESMO 2016
-
Pfizer Announces Expiration of HSR Waiting Period For Proposed Acquisition of Medivation
-
Pfizer to Acquire Medivation
-
Pfizer To Acquire Medivation
-
Inotek Pharmaceuticals Appoints Patrick Machado, JD, to Board of Directors
-
Medivation Reports Second Quarter 2016 Financial Results
-
Medivation Announces Second Quarter 2016 Financial Results Conference Call and Webcast on August 9, 2016
-
REMINDER: Medivation to Host Conference Call and Webcast Providing Detailed Review of Talazoparib on July 6, 2016
-
Sanofi Enters into Confidentiality Agreement with Medivation and Will be Provided Due Diligence Access and Confidential Information
-
Medivation Enters into Confidentiality Agreements, Including with Sanofi
-
Medivation Announces Conference Call and Webcast Providing Detailed Review of Talazoparib
-
Medivation Voted Top Workplace in San Francisco Bay Area for Fourth Year in a Row
-
Glass Lewis Recommends Medivation’s Stockholders Support the Company’s Current Board
-
Medivation Sends Letter to Stockholders to Set the Record Straight on Sanofi’s Misleading Claims
-
Medivation's Pidilizumab Shows Potential Clinical Benefit and Safety in Children With Diffuse Intrinsic Pontine Glioma (DIPG)
-
MEDIVATION INVESTIGATION ALERT – Andrews & Springer LLC Is Investigating Medivation, Inc. For Potential Breaches of Fiduciary Duty - MDVN
-
Sanofi Announces Expiration of Hart-Scott-Rodino Waiting Period Regarding Proposed Acquisition of Medivation
-
Sanofi Files Definitive Consent Solicitation to Remove and Replace Medivation's Board
-
Medivation Files Definitive Consent Revocation Statement and Mails Letter to Stockholders
-
Sanofi Files Investor Presentation Regarding Proposed Acquisition of Medivation
-
Astellas and Medivation Initiate Phase III Trial of Enzalutamide in Patients with Triple-Negative Breast Cancer
-
Medivation and Astellas Initiate Phase III Trial of Enzalutamide in Patients With Triple-Negative Breast Cancer
-
Medivation Sets Record Date for Sanofi’s Proposed Consent Solicitation
-
Sanofi Requests Record Date for Consent Solicitation to Remove and Replace Medivation's Board of Directors
-
Medivation Files Preliminary Consent Revocation Statement
-
Medivation to Present at the Following Conferences
-
Medivation Urges Stockholders to Reject Sanofi’s Attempt to Replace Medivation Board of Directors
-
Sanofi Files Consent Solicitation To Remove and Replace Medivation's Board
-
Arm of I-SPY 2 TRIAL Investigating Medivation's Talazoparib for Treatment of Breast Cancer Activated
-
Sanofi Files for Hart-Scott-Rodino Notification Regarding Proposed Acquisition of Medivation
-
Medivation Receives Prestigious Award From American Urological Association (AUA)
-
Medivation Reports First Quarter 2016 Financial Results
-
Medivation Reiterates Rejection of Sanofi's Substantially Inadequate Proposal
-
Sanofi Sends Letter to Medivation's Board of Directors
-
Medivation Announces First Quarter 2016 Financial Results Teleconference on May 5, 2016
-
Sanofi Comments on Medivation's Rejection of Proposal
-
Medivation's Board of Directors Unanimously Rejects Sanofi's Unsolicited Proposal
-
Medivation Confirms Receipt of Unsolicited Proposal From Sanofi
-
Sanofi : Sanofi Offers to Acquire Medivation for $52.50 Per Share in Cash
-
Medivation Announces Participation at Upcoming Investor Conferences
-
Medivation Announces First Quarter 2016 Financial Results Teleconference on May 5, 2016
-
Medivation Announces Presentation of Phase 2 Enzalutamide Data Evaluating Potential Immune-Activating Properties in Non-Metastatic Castration Sensitive Prostate Cancer Patients
-
Medivation Announces Presentation of Phase I Talazoparib Combination Data in Several Advanced Cancers
-
CHMP Issues Positive Opinion to Include New Data in European Label for XTANDI(R) (Enzalutamide)
-
CHMP Issues Positive Opinion to Include New Data in European Label for XTANDI® (enzalutamide)
-
Jennifer Jarrett to Join Medivation as Chief Financial Officer
-
Pivotal Phase III Trial of enzalutamide Initiated in Metastatic Hormone Sensitive Prostate Cancer
-
Pivotal Phase III Trial of Enzalutamide Initiated in Metastatic Hormone Sensitive Prostate Cancer
Back to MDVN Stock Lookup
